Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes by Giagounidis, Aristoteles et al.
REVIEW ARTICLE
Practical recommendations on the use of lenalidomide
in the management of myelodysplastic syndromes
Aristoteles Giagounidis & Pierre Fenaux &
Ghulam J. Mufti & Petra Muus & Uwe Platzbecker &
Guillermo Sanz & Larry Cripe &
Marie Von Lilienfeld-Toal & Richard A. Wells
Received: 22 December 2007 /Accepted: 17 January 2008 /Published online: 12 February 2008
# The Author(s) 2008
Abstract Lenalidomide, an oral immunomodulatory
agent, has received approval in the USA from the Food
and Drug Administration (FDA) for the management of
myelodysplastic syndromes (MDS) classified by the
International Prognostic Scoring System (IPSS) as low
risk or intermediate-1 risk and with a deletion 5q (del
(5q)) cytogenetic abnormality. Although some patients
with del(5q) have a relatively good prognosis, all del(5q)
patients will become transfusion-dependent at some point
during the course of their disease. The results of two
clinical trials in more than 160 patients with MDS have
demonstrated clear therapeutic benefits of lenalidomide,
with >60% of patients achieving independence from
transfusion during therapy, irrespective of age, prior
therapy, sex, or disease-risk assessment. The recommen-
dations presented in this review will aid the safe
administration of lenalidomide for the treatment of
patients with low-risk or intermediate-1-risk MDS and a
del(5q) cytogenetic abnormality, and they will help
physicians avoid unnecessary dose reduction or interrup-
tion, thus assuring the best efficacy for patients.
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Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal hematopoietic stem cell disorders character-
ized by ineffective hematopoiesis and leading to peripheral
cytopenias and a genetic instability with enhanced risk of
disease transformation to acute myeloid leukemia (AML).
In the general population, MDS affects approximately
five in every 100,000 individuals and is regarded as a
relatively rare disease [1]. However, its incidence is highest
in people aged >70 years, and in this age group, MDS is the
most frequently occurring malignant hematological disor-
der: twice as frequent as AML, more common than chronic
lymphocytic leukemia, and more common than all other
malignant lymphomas combined [2]. All patients diagnosed
with MDS will eventually die from their disease, and in
about 30%, the disease will progress to AML [3].
Between 40% and 60% of patients with primary MDS
and about 90% of patients with secondary MDS have
chromosomal abnormalities at the time of diagnosis [4].
Chromosomal abnormalities may occur as a single abnor-
mality or as part of a complex karyotype; disease severity
increases with the number of abnormalities. The most
common chromosomal abnormalities are deletions of
chromosome 5 and chromosome 7 and trisomy of chromo-
some 8 [5]. In a subgroup of patients who have an isolated
deletion 5q (del(5q)), termed 5q-syndrome, the clinical
profile is distinct [6]. Typically, this clinical profile includes
macrocytic anemia, a normal to increased platelet count,
mild leukopenia, hypolobulated megakaryocytes in the
bone marrow, a medullary blast count <5%, and an isolated
del(5q) abnormality including a common deleted region
between 5q31 and 5q33 [4, 7]. Consistent with the
observation that disease severity is related to the number
of chromosomal abnormalities, patients with del(5q) plus
additional cytogenetic abnormalities have a worse progno-
sis than those with an isolated del(5q) abnormality [3, 5].
On the basis of the results of an international phase II
trial in 148 patients [8], the oral immunomodulatory,
antiangiogenic, and antineoplastic agent lenalidomide
(Revlimid®; Celgene Corporation, NJ, USA) was approved
in December 2005 by the US Food and Drug Administra-
tion (FDA) for the treatment of patients with transfusion-
dependent International Prognostic Scoring System (IPSS)
classified low-risk to intermediate-1-risk MDS with a del
(5q) cytogenetic abnormality, with or without additional
cytogenetic abnormalities. The first 46 patients recruited
received lenalidomide 10mg/day for 21days every 28-day
cycle, for up to 24weeks. After a protocol amendment, the
remaining 102 patients received lenalidomide 10mg/day on
a continuous dosing schedule [8]. Overall, 67% of patients
who were initially transfusion-dependent achieved transfu-
sion independence, and another 9% achieved a decrease
(≥50%) in the total number of transfusions required during
lenalidomide therapy [8]. Forty-five percent of the 85
evaluable patients in this study achieved a complete
cytogenetic response, irrespective of chromosomal com-
plexity [8].
In January 2007, an international group of MDS special-
ists met to discuss the practical management of lenalidomide
in patients with transfusion-dependent, IPSS-classified low-
risk or intermediate-1-risk MDS and a del(5q) cytogenetic
abnormality. The recommendations presented here are based
on the clinical data derived from the current literature [8, 9],
from the known clinical profile of lenalidomide in other
disorders, and the clinical experience of the panel members
in the practical use of this agent. Although lenalidomide has
been used in IPSS-classified intermediate-2-risk and high-
risk patients and in patients without an associated del(5q)
abnormality, the recommendations presented here focus on
the current approved indication of the drug in the USA.
Selection of patients for lenalidomide therapy
The FDA approved lenalidomide for patients with
transfusion-dependent anemia due to low- or intermediate-
1-risk MDS associated with a del(5q) cytogenetic abnormal-
ity, with or without additional cytogenetic abnormalities.
This is an important limitation, as patients with a complex
karyotype and del(5q) are eligible for treatment only if they
have no more than one cytopenia (i.e., anemia, neutropenia,
or thrombocytopenia) and their medullary bone marrow
blast count is <5%. Furthermore, patients with a bone
marrow blast count up to 10% receive a score of 0.5 points
in the IPSS classification (Table 1)[ 3]. Therefore, in order
to remain in the IPSS intermediate-1-risk category, one
Table 1 International prognostic scoring system for myelodysplastic
syndromes: survival and evolution of acute myeloid leukemia
Score value
Prognostic
variable
0 0.5 1.0 1.5 2.0
Bone marrow
blasts, %
<5 5–10 – 11–20 21–30
Karyotype
a Good Intermediate Poor
Cytopenias
b 0/1 2/3
Scores for risk groups are as follows: Low, 0; Int-1, 0.5–1.0; Int-2,
1.5–2.0; and High, ≥2.5
aGood: normal, −Y, isolated del(5q), isolated del(20q); poor: ≥3
abnormalities or chromosome 7 anomalies; intermediate: other
abnormalities
bNeutrophils <1800×10
6/l, hemoglobin <10 g/dl, platelets <100×
10
9/l
Table reproduced with permission from [3] © The American Society
of Hematology
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mosome 7) or two or more peripheral cytopenias are
allowed, but not both. Although teratogenicity has not been
reported with lenalidomide, as it is an analogue of
thalidomide, women of childbearing potential should have
two negative pregnancy tests performed within 14days
prior to lenalidomide intake.
Lenalidomide therapy is effective regardless of prior
erythropoietin [8, 9] or prior thalidomide therapy [9], and
those previous therapies should not be regarded as contra-
indications for its use, although concurrent therapy with
erythropoietin is not recommended, owing to concerns
regarding venous thromboembolism.
Clinical data have shown that the frequency of response
to lenalidomide is similar across all age groups evaluated
[8]. Importantly, the overall adverse-event burden did not
increase in older patients, but serious adverse events were
more frequent in patients aged over 65years compared with
younger patients (54% vs. 33%, respectively) [10].
Although the impact of renal impairment on lenalido-
mide efficacy or toxicity in patients with MDS has not
been evaluated, the risk of toxicity is expected to be
greater in patients with impaired renal function because
lenalidomide is renally excreted [11]. In patients with
known renal impairment, the expert panel support the
dosing schedule proposed by Chen et al., which is based on
creatinine clearance (Table 2)[ 11]. As advancing age is
associated with declining renal function, it is recommended
that patients older than 65years who are prescribed
lenalidomide are monitored carefully throughout their
treatment (Table 3).
Likewise, the safety, efficacy, and pharmacokinetics of
lenalidomide therapy have not been fully investigated in
patients with evidence of hepatic impairment, or those with
frank hepatic dysfunction. Clinical trials conducted to date
have excluded patients with inadequate hepatic function,
with individual trials using different serum transaminase
measures as exclusion criteria; most trials excluded patients
with serum transaminase levels greater than three times the
upper limit of normal.
Pharmacokinetic studies have revealed that the co-
administration of lenalidomide with digoxin may increase
the maximal digoxin concentration, although the area under
the concentration–time curve remained unchanged [10].
Importantly, lenalidomide does not interact with the
cytochrome P450 system, and so, can be confidently co-
administered with other medications metabolized by this
route (Celgene data on file) [10]. This latter finding is
particularly relevant for older patients, who may be more
likely to be receiving concomitant medications for co-
morbidities. The expert panel concurred with the current
prescribing information for lenalidomide and recommended
that patients taking digoxin should have their digoxin
plasma levels monitored periodically (Table 3).
Treatment with lenalidomide in del(5q) MDS
The time-to-response during lenalidomide therapy was
evaluated in the larger of the two pivotal clinical trials
[8]. For most patients, the median time to initiation of the
transfusion-independent period was 4.6weeks, but
responses have been noted to take up to 12months [8].
Therefore, the expert panel recommends a treatment
duration of at least 4months in order to obtain an initial
response (Table 4). Patients were followed for a median of
104weeks, but as more than half of them remained
transfusion-free at this assessment point, the median
duration of transfusion independence could not be calcu-
lated. Encouragingly, among the pooled patients with MDS
with a del(5q) abnormality from the two studies [8, 9],
transfusion independence and major erythroid response
were maintained for a median duration of at least 2years
[12]. Even though there are anecdotal reports of long-
lasting erythroid remissions in some patients with hemato-
logical complete response who discontinued lenalidomide,
the panel recommends continuation of lenalidomide treat-
ment in responders for as long as it is tolerated. In patients
where the dose has initially been reduced for mild adverse
events, dose escalations may be considered (Table 4). In
responders with high ferritin levels due to long transfusion
histories who achieve normal hemoglobin levels, lenalido-
mide treatment should be continued and therapeutic
phlebotomy be considered to reduce the secondary iron
overload. In responders who discontinue due to adverse
events, the panel recommends checking for response
continuation before initiating another treatment (Table 4).
Preliminary data show that prolonged treatment with
Table 2 Recommended dose adjustments for patients with impaired
renal function
a
Renal impairment Dose
Mild 10 mg (full dose) every 24 h
(80>CLcr≥50 ml/min)
Moderate 5 mg every 24 h
(30≤CLcr<50 ml/min)
Severe 5 mg every 48 h
(CLcr<30 ml/min,
not requiring dialysis)
End-stage renal disease 5 mg three times a week after
each dialysis (CLcr<30 ml/min,
requiring dialysis)
aRecommendationsbasedonapharmacokineticstudybyChenetal.[11]
CLcr creatinine clearance
Table adapted from [11] © 2007 SAGE Publications. Adapted by
permission of SAGE Publications, Inc.
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myeloid leukemia [13]. Of note, there are reports of patients
acquiring additional cytogenetic abnormalities while on
lenalidomide [8], but at this time the relevance of this
phenomenon is not entirely clear. Until there is data to the
contrary, patients with continuous hematological response
should remain on the drug. Patients losing their response
and developing a complex karyotype should be approached
as they would be in the absence of lenalidomide, and
alternative therapies, including transplantation, should be
considered.
Tolerability of lenalidomide in del(5q) MDS
Lenalidomide has been shown to be well tolerated in the
two clinical trials reported to date [8, 9]. The most
commonly reported adverse events of grade 3 or 4 severity
were neutropenia (55%), thrombocytopenia (44%), anemia
(7%), leukopenia (6%), rash (6%), diarrhea (3%), pruritus
(3%), pneumonia (3%), and fatigue (3%) [8].
Management of hematological adverse events
Hematological adverse events, including neutropenia and
thrombocytopenia, were the most common adverse events
with lenalidomide therapy and the most frequent reasons
for dose adjustment [9]. As such, thrombocytopenia and
neutropenia should be expected to occur in most patients—
in fact, they appear to be associated with a higher likelihood
of a response to therapy [14]. In general, regular monitoring
of blood cell counts is recommended (Table 3).
The majority of hematological adverse events (62%)
occurred early in the course of treatment (within the
first 8weeks) [8]. Grade 3 or 4 neutropenia was reported
in 55% of patients [8]. Monitoring and, in some cases,
Table 4 Recommendations for treatment duration
Recommendation(s)
Initial treatment Treatment should be continued for at least 4 months in order to obtain an initial response
Patients who
Have a complete hematological
response
Continue lenalidomide therapy for as long as it continues to be well tolerated to avoid relapse
(both erythroid and cytogenetic)
Have a partial response Continue lenalidomide therapy, and consider an escalation of the lenalidomide dose to a maximum
of 10 mg per day, if tolerable
Discontinue treatment because of
adverse events
Patients should not begin another therapy immediately; it is recommended to wait 8–12 weeks to
determine whether the response continues
Table 3 Recommendations for
laboratory monitoring during
treatment
BM Bone marrow, FBC full
blood count, T4 thyroxine, TSH
thyroid-stimulating hormone
Function Test Recommendation(s)
Kidney
function
Creatinine Every 4 weeks in patients aged 65 years and older
Blood FBC Weekly monitoring of full blood count mandatory for
the first 2 months (it may be continued for 5 months).
Biweekly or monthly monitoring should be considered
thereafter, depending on hematological status.
If treatment is interrupted in patients who had a previous
episode of neutropenia or thrombocytopenia while on
lenalidomide treatment, the same monitoring
guidelines apply at re-initiation
Thyroid
function
TSH, T4 Monitor every month during the course of treatment
In case of loss of response during lenalidomide
treatment
Gonadal
function
Testosterone In case of loss of response during lenalidomide
treatment
Digoxin Digoxin In patients concomitantly taking Digoxin, the plasma
level should be monitored periodically
Pregnancy
test
Urine test Day −14 and day 0 at initiation of therapy, monthly
thereafter (in women of childbearing potential)
Bone
marrow
BM aspiration and cytogenetic
testing; Trephine biopsy
optional
At commencement of therapy.
In case of loss of response to rule out progressive
disease or cytogenetic evolution
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factor (G-CSF) is recommended (Tables 3 and 5,a n d
Fig. 1). Neutropenic sepsis was the only reported cause
of death (occurring in three patients) that was regarded
as possibly related to the study drug [8], therefore,
patients should receive clear guidance on how to react
in the event of febrile neutropenia (Table 5). Grade 3 or
4 thrombocytopenia was observed in 44% of patients [8].
In some thrombocytopenic patients, interruption of lena-
lidomide treatment may be necessary (Table 5 and Fig. 1).
Lenalidomide has not been tested in patients with a
baseline neutrophil count <500 × 10
6/l or baseline platelet
count <50 × 10
9/l.
In the opinion of the panel, patients presenting with a
neutrophil count <1,000 × 10
6/l prior to the start of
lenalidomide therapy can still be treated with lenalidomide
a 
Neutropenia
Neutrophils <1000X106/l Neutrophils <500X106/l
Introduce G-CSF or 
temporarily 
discontinue 
lenalidomide therapy
Monitor
Interrupt lenalidomide 
therapy
After one week of 
discontinuation and  
neutrophils ≥  750X106/l
Reintroduce 
lenalidomide 
at a lower 
dose level
After one week of 
discontinuation and  
neutrophils <750X106/l
Monitor
b  
Thrombocytopenia
Platelets < 25x109/l at 
presentationa
Platelets < 25x109/l
during therapy
Consider initiating 
lenalidomide with 
platelet support
Monitor
Interrupt lenalidomide 
therapy until platelets 
> 50x109/l
Restart lenalidomide at 
a lower dose level
Monitor
Fig. 1 Recommendations for the management of a neutropenia and b thrombocytopenia.
aNo consensus was reached, recommendation is based
on the opinion of some of the panel members G-CSF granulocyte colony-stimulating factor
Ann Hematol (2008) 87:345–352 349if G-CSF is co-administered. When neutropenia occurs
during lenalidomide therapy, interruption of the lenalido-
mide treatment schedule might be necessary (Table 5 and
Fig. 1). When thrombocytopenia (platelet count <25 × 10
9/l)
is diagnosed at presentation, based on the rationale that
once a response is achieved thrombocytopenia is likely to
resolve, some experts would consider administering lenali-
domide with platelet support (Table 5 and Fig. 1). However,
other experts advise against the use of lenalidomide in
patients with a platelet count <50 × 10
9/l because there is a
risk of sustained deterioration of thrombocytopenia, despite
an erythroid response. In some patients responding to
lenalidomide, polycythemia may occur [8]; if appropriate,
therapeutic phlebotomy or interruption of lenalidomide
therapy may be considered (Table 5).
Grade 3 or 4 venous thromboembolism (VTE) was
observed in 3% of patients [8]. Generally, the risk of
VTE is increased if there is a history of superficial vein
thrombosis, or previous VTE [15, 16]. It is unknown if
this applies to patients treated with lenalidomide as well.
Nevertheless, these patients should be carefully moni-
tored. In patients with a history of previous VTE, low-
molecular-weight heparin should be used to prevent
recurrent thrombosis. Although aspirin is effective in the
prevention of thrombosis in multiple myeloma, aspirin
cannot be recommended alongside lenalidomide as lena-
lidomide frequently leads to grade 3 or 4 thrombocytope-
nia in patients with MDS with del(5q). There are
insufficient data on low-dose coumadin treatment for the
prophylaxis of VTE, and therefore the panel did not
recommend its use. Of particular relevance to patients
with MDS, VTE risk is increased by concomitant
erythropoietin use [17]. Since the incidence of VTE in
patients with lenalidomide-treated MDS is generally low
[8], prophylaxis in patients without antecedents of VTE is
not recommended. If VTE does occur, it should be treated
according to standard protocols. Treatment with lenalido-
mide should be interrupted until stable anticoagulation is
achieved and then carefully reintroduced (Table 5). Once
VTE has occurred during lenalidomide therapy, patients
must remain on anticoagulation therapy as lenalidomide
treatment continues.
Table 5 Recommendations for the management of hematological adverse events
Recommendation(s)
Neutropenia For treatment recommendations for neutropenia see Fig. 1
Febrile neutropenia Provide patients with clear guidance on how to react in the event of febrile neutropenia (patient education,
specialized hematological care at all times, and broad-spectrum antibiotics within 3 h of fever onset)
Thrombocytopenia For treatment recommendations for thrombocytopenia see Fig. 1
VTE VTE prophylaxis is not generally recommended in patients with MDS. Combining lenalidomide with
erythropoietin is also not recommended.
If erythropoietin is used, be aware of a potentially increased risk of VTE. Patients should be informed about
the risk of VTE and monitored for symptoms
If VTE does occur, interrupt lenalidomide treatment, treat the VTE, and carefully re-introduce lenalidomide
once stable anticoagulation has been established
Polycythemia Lenalidomide should be continued and phlebotomy considered, depending on ferritin levels. Although
polycythemia is usually transient, treatment interruption may be necessary if additional risk factors for
VTE are present
MDS myelodysplastic syndromes, VTE venous thromboembolism
Table 6 Recommendations for management of non-hematological adverse events (NHAEs)
NHAE Recommendation(s)
Rash Usually resolves within 2–3 weeks, no interruption of lenalidomide treatment needed
If required treat with unselective antihistamines (e.g. clemastine), topical steroids, or a short course (14 days)
of oral 10 mg prednisone
If rash is severe or persists after treatment, lenalidomide should be interrupted until rash resolves. In the
experience of the panel, lenalidomide can be restarted thereafter without recurrence of rash
Diarrhea Treat symptomatically after ruling out other underlying causes
Hypothyroidism In case of hypothyroidism, thyroid replacement therapy must be initiated
Other NHAEs Treat symptomatically after ruling out other underlying causes such as anemia or autoimmune disorders
350 Ann Hematol (2008) 87:345–352Management of non-hematological adverse events
Unlike thalidomide, lenalidomide does not lead to dose-
dependent peripheral neuropathy or somnolence [18], but
other non-hematological adverse events (NHAEs) may
occur. The most common NHAEs (all grades) associated
with lenalidomide therapy are diarrhea (49%), pruritus
(42%), rash (36%), and fatigue (31%) [10]. The most
commonly reported grade ≥3 NHAEs were rash (6%),
fatigue (3%), diarrhea (3%), and pruritus (3%) [8]. In
general, should NHAEs arise during lenalidomide therapy,
alternative causes should be ruled out and symptomatic
treatment initiated (Table 6). Dry skin and pruritus occur
regularly, and itching of the scalp is a characteristic adverse
event during the first few weeks of therapy. These NHAEs
are usually self-limiting and seldom need treatment.
Unselective antihistamines (e.g., clemastine) are usually
helpful. In severe cases, a short course of systemic cortico-
steroids (10mg of prednisone or equivalent), or local steroid
application may be helpful. Rash often resolves spontane-
ously with time [19], and the panel do not recommend
discontinuation of lenalidomide treatment should rash arise;
however, in patients with severe or persistent rash, the
temporary interruption of lenalidomide may be necessary
(Table 6).
Diarrhea is a frequent problem and may impact on a
patient’s quality of life. Patients with known lactose
intolerance should add lactase to their diet, as lenalido-
mide capsules contain small amounts of lactose. Diverse
symptomatic therapies have been reported to be effec-
tive in those patients, including, but not limited to,
loperamide, pipaverium bromide, uzara root extract, and
tinctura opii. Muscle cramps have been reported by a
number of patients after a variable time of lenalidomide
intake. Magnesium dietary supplements may be tried,
but are usually of limited value. Quinine sulphate (up to
200mg thrice-daily) works well, however, physicians
should check for other cytochrome-P450-interacting
drugs (e.g., sotalol, terfenadine, astemizole, voricona-
zole, erythromycin, rifampicin, and cisapride) that might
prolong QT time in these patients. Patients who
experience fatigue will be likely to benefit from
counselling [20], and in cases of severe fatigue, dose
reduction may be needed. Hypothyroidism has been
reported in approximately 7% of patients [10]. It is almost
exclusively of autoimmune cause. Patients should be
screened for hypothyroidism every other month during
the course of treatment (Table 3). If hypothyroidism is
confirmed, hormone replacement therapy is indicated
(Table 6). Patients losing their response to lenalidomide
during treatment may have developed either hypothyroid-
ism or hypogonadism, and should be screened for both
conditions.
Conclusions
The approval of lenalidomide for the treatment of MDS
patients with low-risk or intermediate-1-risk disease with a
deletion of chromosome 5q represents a significant step
forward for this underserved group of patients. The key
goal of the strategies presented here is to avoid unnecessary
dose delays and reductions, and to maximize probability of
response. Patient selection is straightforward, as efficacy
does not appear to be influenced appreciably by relevant
prognostic factors including age, prior erythropoietin
therapy, sex, French–American–British type, or IPSS score.
Treatment should be continued for a minimum of 4months
to ensure treatment response. Neutropenia and thrombocy-
topenia are the most common adverse events during
lenalidomide therapy but can be managed by the introduc-
tion of G-CSF and dose interruption. Other side-effects are
generally manageable, and a range of simple (prophylactic)
interventions are recommended to address the more
common and more serious associated adverse events.
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